40 results about "Oligodendrocyte progenitor" patented technology

The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations.

The present invention is directed to a method of separating oligodendrocyte cells or progenitor cells thereof from a mixed population of cells. It comprises selecting a promoter which functions only in the oligodendrocyte cells or progenitor cells thereof, introducing a nucleic acid molecule encoding a fluorescent protein under control of that promoter into the mixed population cells, allowing the oligodendrocyte cells or progenitor cells thereof to express the fluorescent protein, and separating the fluorescent cells from the mixed population cells, where the separated cells are the oligodendrocyte cells or progenitor cells thereof. The invention also relates to the isolated and enriched human oligodendrocyte cells or progenitor cells thereof.

Described is the efficient and robust generation of oligodendrocyte progenitor cells (OPCs) and oligodendrocytes from pluripotent stem cells (PSCs). The protocols provided recapitulate the major steps of oligodendrocyte differentiation, from neural stem cells to OLIG2⁺ progenitors, and then to 04⁺ OPCs, in a significantly shorter time than the 120-150 days required by previous protocols. Furthermore, 04+ OPCs are able to differentiate into MBP⁺ mature oligodendrocytes in vitro, and to myelinate axons in vivo when injected into immuno-compromised Shiverer mice, providing proof of concept that transplantation of PSC-derived cells for remyelination is technically feasible.

The invention belongs to the field of biomedicine, and relates to a method for differentiation of embryonic stem cells into nerve cells through in vitro induction, especially to a method for induction of Olig2<+>-GFP<+>-mES nerve cell differentiation through a purine derivative Purmorphamine, and uses thereof. According to the present invention, an embryoid body mediated nerve induction method is adopted, Olig2-GFP<+>-mES is adopted as a cell model, a purine derivative Purmorphamine and all-trans retinoic acid are combined to carry out directed induction on the Olig2-GFP<+>-mES cells to obtain spinal motor neurons and oligodendrocyte progenitor cells through differentiation; experiment results show that the Purmorphamine can be used as a substitute of SHH, can effectively induce Olig2<+>-GFP<+>-mES differentiation to obtain high purity and function spinal motor neurons and oligodendroglial cells, and can cause expression changes of related genes; and transplant experiment results show that the induced nerve cells can promote partial function and morphology restoration after rat spinal cord injury, and have effects of spinal cord injury regeneration promotion and function reconstruction.

The present invention relates to a method of modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter. Both of these methods involve administering an agonist or antagonist of one or more molecules set forth in Tables 1 and/or 2 to the neural progenitor cells. Also disclosed is a method of using an inhibitor of sterol synthesis to differentiate oligodendrocyte progenitor cells to oligodendrocytes.

The invention relates to a method for obtaining human OPCs (Oligodendrocyte Progenitor Cells) and an OPCs medium. According to the method, neural stem cells are used as a sorting source, the human OPCs can be obtained by separation through an immunomagnetic bead method, and a more economical medium suitable for OPCs in vitro culture and passage, so that a great amount of high-purity human OPCs can be obtained in a short time, and a new choice is provided for clinical application.

The invention provides a culture medium for differentiating neural stem cells into oligodendrocyte progenitor cells. The culture medium does not contain exogenous factors, so that pollution of the exogenous factors is avoided, and the oligodendrocyte progenitor cells can be efficiently differentiated. The invention further provides a method for preparing the oligodendrocyte progenitor cells by using the culture medium. By use of the method provided by the invention, the differentiation efficiency of the oligodendrocyte progenitor cells is improved on the premise of increasing the yield of theoligodendrocyte progenitor cells.

The present invention relates to a composition for inducing direct transdifferentiation into oligodendrocyte progenitor cells (OPCs) from somatic cells, the composition containing at least one protein selected from the group consisting of direct transdifferentiation factors OCT4, SOX1, SOX2, SOX10, OLIG2, NKX2.2, and NKX6.2, a nucleic acid molecule coding the protein, or a vector including the nucleic acid molecule introduced thereinto; a pharmaceutical composition for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for preventing or treating spinal cord injuries or demyelination diseases; a cell therapy agent for treating spinal cord injuries or demyelination diseases; a composition for screening drugs for the treatment of spinal cord injuries or demyelination diseases; a 3D printing biomaterial composition for manufacturing artificial tissues for the treatment of spinal cord injuries or demyelination diseases; and a method for direct transdifferentiation into oligodendrocyte progenitor cells from somatic cells. According to the present invention, the oligodendrocyte progenitor cells are prepared from somatic cells through direct transdifferentiation, and thus can be favorably utilized for the treatment of spinal cord injuries and demyelination diseases.

The invention provides a differential medium for obtaining oligodendrocyte progenitor cells and proliferation thereof by processing mesenchymal stem cells through eleutheroside. The differential medium comprises a liquid basal medium, and also comprises 1-100ug/mL eleutheroside, 1 to 20 percent of fetal calf serum, 5 to 300ng/mL human epidermal growth factor (EGF) and 5 to 300ng/mL basic fibroblast growth factor (bFGF) based on the volume of the liquid basal medium. The invention also provides a method for preparing an eleutheroside processing kit by using the differential medium, and also provides a medicinal composition comprising the oligodendrocyte progenitor cells prepared by the method and used for treating nerve system disease. By using the differential medium, the method has the advantages that: the mesenchymal stem cells can be efficiently differentiated and the oligodendrocyte progenitor cells are obtained. The medicinal composition for treating diseases such as traumatic spinal cord injury, multiple sclerosis and the like can repair injured nerve cells in vivo and eliminate neurologic disorder.

Methods for differentiating human pluripotent stem cells to dorsal neuroectoderm progenitors and further to glial progenitor cells and oligodendrocyte progenitor cells (OPCs) using inhibitors of BMP signaling and MAPK/ERK signaling are provided. Also provided are cells and cellular compositions obtained by such methods, and uses of such cells. Further provided are methods and protocols for efficiently differentiating human pluripotent stem cells to OPCs in the absence of the ventralizing morphogen SHH or a SHH signaling activator. The methods of the present disclosure reproducibly produce dorsal neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.

The invention provides a culture medium, an induction culture method of oligodendrocyte progenitor cells and application. The culture medium combination provided by the invention comprises the following culture medium in the induced differentiation stage: embryonic bodies, neural epithelial cells, Pre-OPCs and hOPCs. In each stage, a specific induction culture medium is adopted for adherent culture. Experimental results show that the induction rate of differentiation of hESC and hiPSC to hOPC can be remarkably increased, the purity of hOPC is obviously improved, and the induction time is greatly shortened compared with that of traditional suspension culture. The induction culture method is suitable for differentiation of human embryonic stem cells and human induced pluripotent stem cells to oligodendrocyte progenitor cells. Experiments show that OPC obtained through induction culture can obviously reduce the loss of injured brain region tissues, can improve and enhance the recovery of the injured brain region tissues, and can be used for cell transplantation to treat cerebral nervous system diseases such as cerebral apoplexy injury.

A method for promoting differentiation of clonogenic neural stem cells (NSCs), comprising administering to a patient in the need of such promoting a coumarin compound represented by formula I or by formula II. The representative coumarin compounds include 7-hydroxycoumarin, daphnoretin, scopoletin, edgeworin, aesculetin and esculetin-6-β-D-glucopyranoside. The coumarin compounds showed significant activity of directing the differentiation of NSCs in pharmacological test and thereof could be used to prepare drugs to direct NSCs differentiated to oligodendrocyte progenitor cells (OPCs) for the treatment of demyelinating diseases or spinal cord injury. The drug could be a pure coumarin compound or a pharmaceutical composition comprising a therapeutical dose of a coumarin compound as active ingredients and a pharmaceutically-acceptable carrier. The content of the active ingredients in the pharmaceutical composition is between 0.1% and 99.5% by weight.

One form of the present invention is directed to a method of remyelinating demyelinated axons by treating the demyelinated axons with oligodendrocyte progenitor cells under conditions which permit remyelination of the axons. Another aspect of the present invention relates to a method of treating a subject having a condition mediated by a loss of myelin or a loss of oligodendrocytes by administering to the subject oligodendrocyte progenitor cells under conditions effective to treat the condition mediated by a loss of myelin or a loss of oligodendrocytes. A further aspect of the present invention relates to an in vitro method of identifying and separating oligodendrocyte progenitor cells from a mixed population containing other mammalian brain or spinal cord cell types. This further aspect of the present invention involves removing neurons and neuronal progenitor cells from the mixed population to produce a treated mixed population. Oligodendrocyte progenitor cells are then separated from the treated mixed population to form an enriched population of oligodendrocyte progenitor cells.

Methods and compositions for making and using pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury are disclosed.

Provided are compositions and methods comprising a MAChR antagonist/inverse agonist/partial agonist and a histamine H3 receptor antagonist/inverse agonist/partial agonist for increasing proliferation Oligodendrocyte Progenitor Cells (OPCs) into mature, myelinating oligodendrocytes, and related methods of treating demyelination disorders.